Otenabant
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
|
|
| CAS Number | 686344-29-6  |
| PubChem (CID) | 10052040 |
| ChemSpider | 8227602  |
| UNII | J8211Y53EF |
| KEGG | D09362 |
| ChEMBL | CHEMBL562668 |
| Chemical and physical data | |
| Formula | C25H25Cl2N7O |
| Molar mass | 510.4 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also[edit]
References[edit]
- ^ Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
- ^ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ^ http://www.pfizer.com
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
